Respiratory procedures

JP2023549855A5Inactive Publication Date: 2024-11-20HOFSETH BIOCARE AS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023528658
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-06-17
Filing Date
2021-11-15
Publication Date
2024-11-20
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

There are subgroups of patients with respiratory conditions such as asthma who are refractory to conventional respiratory treatments, including steroid therapy, and exhibit elevated eosinophil levels leading to chronic inflammation and resistance to medical and surgical interventions.

Method used

The use of lipopeptides, such as microcholin and its analogues, is administered to target these refractory patients, reducing eosinophil effector function and addressing chronic inflammation through oral and aerosol delivery methods.

Benefits of technology

The lipopeptides effectively reduce eosinophil activity, alleviating symptoms of chronic inflammation and improving treatment outcomes in patients resistant to conventional therapies, including reducing the need for assisted breathing and enhancing anti-inflammatory efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2022108883000001
    Figure 2022108883000001
  • Figure 2022108883000002
    Figure 2022108883000002
  • Figure 2022108883000003
    Figure 2022108883000003
Patent Text Reader

Abstract

Provided herein is a method for treating certain inflammatory and / or respiratory conditions, disorders and diseases in humans using a composition comprising lipopeptide (including microcorrin).The composition is administered orally.Suitable humans for such treatment include those who are largely resistant to medical and surgical intervention (e.g., steroid treatment).The composition described herein has also been found to reduce eosinophil effector function.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Cross-reference of related applications This application claims priority to U.S. Provisional Patent Application No. 63 / 114,976 filed on 17 November 2020 and U.S. Provisional Patent Application No. 63 / 211,972 filed on 17 June 2021 (each of which is incorporated herein by reference in whole).

[0002] field This disclosure relates to the use of lipopeptides (including microcholine and its analogues) for respiratory treatment in general, and more specifically, for treating respiratory conditions, diseases, or disorders (e.g., asthma) in a subgroup of patients who are resistant to steroid treatment. [Background technology]

[0003] background Inflammation is a major challenge in immunology. On the one hand, the physiological changes associated with inflammation enable rapid responses to external threats that would otherwise likely lead to the extinction of the human species. On the other hand, chronic inflammation, in which aging or external stressors keep the immune system hyperactive, can contribute to many debilitating diseases ranging from Alzheimer's to diabetes and bronchial asthma.

[0004] Eosinophils are a type of white blood cell found in tissues throughout the body and are continuously replenished from the bone marrow. Typically, eosinophils have a lifespan of two days in the blood, but in inflammatory conditions (e.g., infections and allergic diseases), their lifespan can be extended to two weeks by eosinophil-activating cytokines. See Park YM & Bochner BS, Allergy Asthma Immunol Res. 2010, 2:87-101. Eosinophil count is a blood test that measures the amount of eosinophils in the human body. Elevated levels (usually measured during a conventional complete blood count) indicate an infection or allergy. Activated eosinophils (which are promoted by eosinophil-activating cytokines under inflammatory conditions) are a major source of reactive oxygen species, cytotoxic proteins, and pro-inflammatory cytokines. They signal the activation of commensal tissue cells such as epithelial cells, endothelial cells, and fibroblasts, leading to the progression of inflammation and mucus secretion. Eosinophils are therefore potent activators and regulators of diseases such as bronchial asthma, atopic dermatitis, and ulcerative colitis. See Hogan SP, Int Arch Allergy Immunol. 2007, 143(Suppl 1):3-14; Simon D et al., Allergy. 2004, 59:561-570; Wedemeyer J & Vosskuhle K., Best Pract Res Clin Gastroenterol. 2008, 22:537-549. Furthermore, in asthma patients, levels of eosinophil granule proteins such as eosinophil cationic protein (ECP) and eosinophil peroxidase (EPO) correlate strongly with the severity of asthma. See Parra A et al., J Investig Allergol Clin Immunol. 1999; 9:27-34. Eosinophilic inflammation of the upper respiratory tract can also occur independently of allergies, as observed in subjects with chronic sinusitis (CRS). See Hutcheson PS et al., J Rhinol Allergy. 2010, 24:405-408. Such individuals represent a distinct subgroup that is largely resistant to medical and surgical interventions and can show immediate benefit from therapies targeting eosinophil expansion, proliferation, and effector function. [Prior art documents] [Non-patent literature]

[0005] [Non-Patent Document 1] Parra A et al., J Investig Allergol Clin Immunol. (1999)9:27~34 [Non-Patent Document 2] Hutcheson PS, et al., J Rhinol Allergy. (2010)24:405~408 [Overview of the project] [Means for solving the problem]

[0006] concise summary In several aspects, respiratory treatments (e.g., asthma treatments) using lipopeptides are provided herein. In some embodiments, the lipopeptides are microcholine and its structural analogs. In some variations, microcholine A, microcholine B, or a combination thereof are administered in respiratory treatments.

[0007] In some embodiments, the asthma is bronchial asthma. In certain embodiments, treatments are provided that target a subgroup of patients (e.g., asthma patients) who are substantially resistant to medical and surgical interventions (including steroid therapy).

[0008] A method is provided for treating an inflammatory condition, disorder, or disease in a person in need in a particular context, the method comprising the step of orally administering to the person an effective dose of a composition comprising at least one lipopeptide (e.g., at least one microcholine) or a structural analog thereof to treat the inflammatory condition, disorder, or disease.

[0009] A method is provided for treating a respiratory condition, disorder, or disease in a person in need in a particular context, the method comprising the step of orally administering to the person an effective dose of a composition comprising at least one lipopeptide (e.g., at least one microcholine) or a structural analog thereof to treat the respiratory condition, disorder, or disease.

[0010] A method is provided for reducing eosinophil effector function in a person in need in a particular situation, the method comprising the step of administering to the person a composition comprising at least one lipopeptide (e.g., comprising at least one microcholine) or a structural analog thereof to reduce eosinophil effector function.

[0011] In other aspects, a container is provided which comprises a composition comprising at least one lipopeptide (e.g., comprising at least one microcholine) or a structural analog thereof; and a manufactured article which comprises a label containing instructions for the use of such composition.

[0012] In other aspects, a kit is provided which includes a dosage form of a composition comprising at least one lipopeptide (e.g., comprising at least one microcholine) or a structural analog thereof, and a package insert containing instructions for the use of such a composition.

[0013] In some variations of the aforementioned aspects, the dosage form is a syrup, chewable, capsule, or softgel. In other variations, the compositions provided herein are formulated for aerosol delivery. [Modes for carrying out the invention]

[0014] Detailed explanation The foregoing description provides exemplary methods, parameters, etc. However, it should be recognized that such description is provided as an example of an exemplary embodiment, and is not intended to be a limitation on the scope of this disclosure.

[0015] In some cases, methods for treating inflammatory conditions, disorders, or diseases in humans where necessary are provided herein, by orally administering a composition comprising at least one lipopeptide.

[0016] In some embodiments, the lipopeptide is microcholine. In one embodiment, the lipopeptide is microcholine A. In other embodiments, the lipopeptide is [2,4-alkyl-substituted octanoyl]-[N-methylamino acid having a hydrophobic side chain]-[amino acid having a polar uncharged side chain]-[N-methylamino acid having a hydrophobic side chain]-N-[(4-hydroxy-2-pyrrolidinyl)carbonyl]-5-methyl-3-pyrrolin-2-one.

[0017] In some embodiments, the lipopeptide is a microcholine analog. In one embodiment, the lipopeptide is an analog of microcholine A or microcholine B. In other embodiments, the lipopeptide is branched alkyl-[N-methylamino acid with hydrophobic side chain]-[amino acid with polar uncharged side chain]-[N-methylamino acid with hydrophobic side chain]-N-[(4-hydroxy-2-pyrrolidinyl)carbonyl]-5-methyl-3-pyrrolin-2-one. In certain variations, the branched alkyl is at the following positions on the exemplary alkyl chain shown below: [ka] It refers to the branching at positions 1 and 3 of the alkyl chain.

[0018] In yet another embodiment, the lipopeptide is branched alkyl-[N-methylamino acid having a hydrophobic side chain]-[amino acid having a polar, uncharged side chain]-[N-methylamino acid having a hydrophobic side chain]-N-[(4-hydroxy-2-pyrrolidinyl)carbonyl]-N-[pyrrole-2,5-dione].

[0019] In other embodiments, the lipopeptide is alkenyl-[N-methylamino acid having a hydrophobic side chain]-[amino acid having a polar uncharged side chain]-[N-methylamino acid having a hydrophobic side chain]-N-[(4-hydroxy-2-pyrrolidinyl)carbonyl]-5-methyl-3-pyrrolin-2-one, or alkenyl-[N-methylamino acid having a hydrophobic side chain]-[amino acid having a polar uncharged side chain]-[N-methylamino acid having a hydrophobic side chain]-N-[(4-hydroxy-2-pyrrolidinyl)carbonyl]-N-[pyrrole-2,5-dione], or alkenyl-[N-methylamino acid having a hydrophobic side chain]-[amino acid having a polar uncharged side chain]-[N-methylamino acid having a hydrophobic side chain]-N-[pyrrolidinyl-2-carbonyl]-N-[pyrrole-2,5-dione].

[0020] In one variation, the lipopeptide is alkenyl-[N-methylamino acid with hydrophobic side chain]-[amino acid with polar uncharged side chain]-[N-methylamino acid with hydrophobic side chain]-N-[(4-hydroxy-2-pyrrolidinyl)carbonyl]-5-methyl-3-pyrrolin-2-one, or alkenyl-[N-methylamino acid with hydrophobic side chain]-[amino acid with polar uncharged side chain]-[N-methylamino acid with hydrophobic side chain]-N-[(4-hydroxy-2-pyrrolidinyl)carbonyl]-N-[pyrrole-2,5-dione], or alkenyl-[N-methylamino acid with hydrophobic side chain]-[amino acid with polar uncharged side chain]-[N-methylamino acid with hydrophobic side chain]-N-[pyrrolidinyl-2-carbonyl]-N-[pyrrole-2,5-dione]. In one variation, the lipopeptide is alkenyl-[N-methylamino acid with hydrophobic side chain]-[amino acid with polar uncharged side chain]-[N-methylamino acid with hydrophobic side chain]-N-[(4-hydroxy-2-pyrrolidinyl)carbonyl]-5-methyl-3-pyrrolin-2-one, or alkenyl-[N-methylamino acid with hydrophobic side chain]-[amino acid with polar uncharged side chain]-[N-methylamino acid with hydrophobic side chain]-N-[(4-hydroxy-2-pyrrolidinyl)carbonyl]-1H-[pyrrole-2,5-dione], or alkenyl-[N-methylamino acid with hydrophobic side chain]-[amino acid with polar uncharged side chain]-[N-methylamino acid with hydrophobic side chain]-N-[pyrrolidinyl-2-carbonyl]-1H-[pyrrole-2,5-dione].

[0021] Compound of formula (I) In a particular embodiment, the administered composition is at least one compound of formula (I): [ka] These salts (including any isomers of those mentioned above) Here: R 1 is a moiety of at least one optionally substituted amino acid; R 2 is,

Chem.

[0022] In some variations of formula (I), R 1 is at least one optionally substituted amino acid moiety; R 2 is ​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​It contains a sequence of three optionally substituted amino acid moieties. In certain variations, R 1 is, -R 1a -R 1b -R 1c -and here R 1a R is an optionally substituted amino acid moiety having a hydrophobic side chain; 1b R is an optionally substituted amino acid moiety having a polar, uncharged side chain; 1c This is an optionally substituted amino acid moiety having a hydrophobic side chain. In certain variations, R 1a R is an optional substituted amino acid moiety selected from the group consisting of Leu, Val, and Gly; 1b R is an optional substituted amino acid moiety selected from the group consisting of Thr, Ser, and Cys; 1c R is an amino acid moiety selected as needed from the group consisting of Val, Leu, and Gly. In certain variations, R 1a R is an optional substituted amino acid moiety selected from the group consisting of Leu, Val, and Gly; 1b R is a substituted amino acid moiety selected from the group consisting of Thr, Ser, and Cys, in which the oxygen atom of the amino acid moiety is replaced by an acetyl group (-C(O)CH3); 1c This is an optional substituted amino acid moiety selected from the group consisting of Val, Leu, and Gly.

[0024] In some variations, R 1 These are Leu-OAcThr-Val (each Leu and Val is N-alkylated); Val-OAcThr-Leu (each Val and Leu is N-alkylated); Gly-OAcThr-Gly (each Gly is N-alkylated); Leu-OAcSer-Val (each Leu and Val is N-alkylated); or Leu-SAcCys-Val (each Leu and Val is N-alkylated). In one variation, R 1These are Leu-OAcThr-Val (each Leu and Val is N-methylated); Val-OAcThr-Leu (each Val and Leu is N-methylated); Gly-OAcThr-Gly (each Gly is N-methylated); Leu-OAcSer-Val (each Leu and Val is N-methylated); or Leu-SAcCys-Val (each Leu and Val is N-methylated).

[0025] In other variations, R 1 is, -R 1a -R 1b -R 1c -and here R 1a R is an optional substituted amino acid moiety selected from the group consisting of Leu and Phe; 1b is Thr as needed; R 1c This is an aminoVal that has been substituted as needed.

[0026] In a particular variation, R 1 These are Leu-Thr-Val (each Leu and Val is N-methylated); Leu-OAcThr-Val (each Leu and Val is N-methylated); Phe-OAcThr-Val (each Phe and Val is N-methylated); and Phe-Thr-Val (each Phe and Val is N-methylated).

[0027] In the aforementioned variations, the "OAc-amino acid moiety" should be understood as referring to an amino acid moiety in which an acetyl group is substituted (in some cases) via the oxygen atom of the amino acid moiety. For example, "OAcThr" or "OAcSer" refers to threonine or serine substituted with an acetyl group via the oxygen atom of the amino acid side chain, respectively. Similarly, in the aforementioned variations, the "SAc-amino acid moiety" should be understood as referring to an amino acid moiety in which an acetyl group is substituted (in some cases) via the sulfur atom of the amino acid moiety. For example, "SAcCys" refers to cysteine ​​substituted with an acetyl group via the sulfur atom of the amino acid side chain.

[0028] In this specification, the following abbreviations are used for explanation: “Leu” refers to leucine; “Val” refers to valine; “Gly” refers to glycine; “Thr” refers to threonine; “Ser” refers to serine; “Cys” refers to cysteine; “Ala” refers to alanine; “Ile” refers to isoleucine; “Met” refers to methionine; “Phe” refers to phenylalanine; “Tyr” refers to tyrosine; and “Trp” refers to tryptophan. In some variations of amino acids in which they are “N-alkylated”, it should be further understood that the nitrogen in the amino acid skeleton is alkylated. Similarly, in some variations of amino acids in which they are “N-methylated”, the nitrogen in the amino acid skeleton is alkylated with a methyl group.

[0029] In some variations, R 2a It is H. In other variations, R 2a is an alkyl group. In certain variations, R 2a C 1-10 Alkyl, or C 1-5 Alkyl, or C 1-3 It is alkyl. In one variation, R 2a It is methyl.

[0030] In some variations, R 2xIt is H. In other variations, R 2x is an alkyl group that is substituted as needed. In certain variations, the alkyl group is C 1-20 Alkyl, C 1-15 Alkyl, C 1-10 Alkyl, or C 1-5 Alkyl, or C 1-3 It is an alkyl group. In one particular variation, the alkyl group is substituted with -OH. In yet another variation, the alkyl group is substituted with -COOH.

[0031] In some of the variations mentioned above, R 2y It is H. In other variations, R 2y is an alkyl group. In certain variations, the alkyl group is C 1-20 Alkyl, C 1-15 Alkyl, C 1-10 Alkyl, or C 1-5 Alkyl, or C 1-3 It is alkyl or methyl.

[0032] In some variations, R 2x and R 2y These, together with the atoms to which they are bonded, form a five-membered heterocycle, which may be substituted as needed. In certain variations, the heterocycle is pyrrolidine. In certain variations, the heterocycle is unsubstituted or substituted with one or more of -OH or -COOH groups.

[0033] In some variations, R 2 teeth, [ka] And here R 2b is H or OH. In one variation, R 2 teeth, [ka] In certain variations, R 2 teeth, [ka] In certain variations, R 2 teeth, [ka] That is the case.

[0034] In some variations, R 2 teeth, [ka] That is the case.

[0035] In a particular variation, R 2 teeth, [ka] That is the case.

[0036] In some variations, R 3 It is a branched alkyl group. In other variations, R 3 C 1-20 Alkyl, C 1-10 Alkyl, or C 5-10 Alkyl, or C 7-9 It is alkyl. In certain variations described above, the alkyl is either unbranched or branched. In one variation, the alkyl is branched at position 1 and / or 3 of the alkyl chain. In some variations, R 3 teeth, [ka] That is the case.

[0037] Compound of formula (II) In some embodiments, the administered composition is at least one compound of formula (II): [ka] This includes the salt (including any isomer of the aforementioned salt), where: R 1a This is an optionally substituted amino acid moiety having a hydrophobic side chain; R 1b This is an optionally substituted amino acid moiety having a polar, uncharged side chain; R 1c This is an optionally substituted amino acid moiety having a hydrophobic side chain; R 2a is H or an optionally substituted alkyl; R 2b is either H or OH; R 3 It is an alkyl group.

[0038] In a particular embodiment, R 1a , R 1b , R 1c , R 2a , R 2b , and R 3 This may be any of the embodiments or variations of formula (I) described above.

[0039] In a certain variation, the compound of formula (II) is the compound of formula (II-A): [ka] That is the case.

[0040] In certain variations, the compound of formula (II) is the compound of formula (II-B): [ka] That is the case.

[0041] Compound of formula (III) In other variations, the administered composition is at least one compound of formula (III): [Chemical formula] containing the salt (including any isomers of the foregoing), wherein: R 1a is an optionally substituted amino acid moiety having a hydrophobic side chain; R 1b is an optionally substituted amino acid moiety having a polar uncharged side chain; R 1c is an optionally substituted amino acid moiety having a hydrophobic side chain, R 2b is H or OH; R 3 is alkyl.

[0042] In certain embodiments, R 1a , R 1b , R 1c , R 2b , and R 3 can be any of the embodiments or variations described above with respect to formula (I).

[0043] In certain variations, the compound of formula (III) is a compound of formula (III-A): [Chemical formula] containing the salt (including any isomers of the foregoing), wherein R 1a , R 1b , R 1c , and R 2b are as defined above with respect to formula (III).

[0044] Compound of formula (IV) In other variations, the composition administered above comprises at least one compound of formula (IV): [Chemical formula] [[ID= R 1 is a moiety of at least one optionally substituted amino acid; R 2 teeth, [ka] And here R 2a is H, oxo, or optionally substituted alkyl; R 2x is an alkyl group that is optionally substituted with -OH or -COOH; R 2y is H or alkyl; or R 2x and R 2y These, together with the atoms to which they are bonded, form a five-membered heterocycle, which may be substituted as needed; R 3 It is Alkenil.

[0045] In a particular embodiment, R 1 , R 2a , R 2x , R 2y and R 3 This may be any of the embodiments or variations of formula (I) described above.

[0046] In a certain variation, the compound of formula (IV) is the compound of formula (IV-A): [ka] or salts thereof (including any isomer of those mentioned above), Here R 2x , R 2y , and R 3 This is defined above with respect to equation (IV), Here: Z is [ka] Or it is an alkoxy, and here R 2a is H, oxo, or optionally substituted alkyl; R 4 is H or alkyl; Each R 5 and R 8 These are, independently, hydrophobic side chains of Ala, Val, Ile, Leu, Met, Phe, Tyr, Trp, or Gly, where the above hydrophobic side chains are substituted as needed; R 6 is H or alkyl; R 7 These are -OH, -O(C=O)alkyl, -SH, or -S(C=O)alkyl.

[0047] In a particular variation, Z is [ka] That is the case.

[0048] In some embodiments, R 2a H is H. In a particular embodiment, R 2a is an alkyl group that is substituted as needed. In some variations, R 2a is an alkyl group. In certain variations, R 2a C 1-10 Alkyl, or C 1-5 Alkyl, or C 1-3 It is alkyl. In one variation, R 2a is methyl. In yet another embodiment, R 2a It is oxo.

[0049] In some variations, R 2x and R 2y These, together with the atoms to which they are bonded, form an unsubstituted or substituted five-membered heterocycle. In certain variations, the above heterocycle is pyrrolidine. In some variations, R 2xand R 2y These, together with the atoms to which they are bonded, form a five-membered heterocycle substituted with -OH. In certain variations, the above heterocycle is a -OH-substituted pyrrolidine. In other variations, the above heterocycle is an unsubstituted pyrrolidine.

[0050] In some variations, R 3 is an alkenil. In certain variations, R 3 C2-C 30 It is an alkenil. In certain variations, R 3 teeth, [ka] This includes any cis and / or trans configurations of such portions.

[0051] In other variations, R 3 It is an omega-3 fatty acid or a derivative thereof. In certain variations, R 3 This is the eicosapentaenoic acid (EPA) portion, the docosahexaenoic acid (DHA) portion, or a derivative of any of the aforementioned.

[0052] In a particular variation, R 5 is the hydrophobic side chain of Leu. In certain variations, R 5 This is the hydrophobic side chain of Phe.

[0053] In some variations, R 6 It is H. In other variations, R 6 is an alkyl group. In certain variations, R 6 C 1-10 Alkyl, or C 1-5 Alkyl, or C 1-3 It is alkyl. In one variation, R 2a It is methyl.

[0054] In a particular variation, R 7 It is -OH. In other variations, R 7 It is -SH. In some variations, R 7 It is an -O(C=O) alkyl group. In some variations, R 7 It is a -S(C=O) alkyl group. In one of the variations mentioned above, the alkyl group is methyl.

[0055] In a particular variation, R 6 It is methyl, and R 7 It is OH.

[0056] In one embodiment: R 3 It is an omega-3 fatty acid or a derivative thereof. In certain variations, R 3 This is the eicosapentaenoic acid (EPA) moiety, or the docosahexaenoic acid (DHA) moiety, or a derivative of any of the above; R 5 is the hydrophobic side chain of Phe; R 6 It is methyl; R 7 It is -OH.

[0057] Exemplary compounds In a particular embodiment, the above composition comprises at least one of the following compounds: [ka] or including salts thereof (including any isomer of those mentioned above).

[0058] In one embodiment, the above composition comprises at least one of the following compounds: [ka] [ka] or a salt thereof.

[0059] In one embodiment, the above compositions include microcholine A or a salt thereof. In several variations, the above compositions include [(2S,3S)-3-[[(2S)-2-[[(2R,4R)-2,4-dimethyloctanoyl]-methylamino]-4-methylpentanoyl]amino]-4-[[(2S)-1-[(2S,4S)-4-hydroxy-2-[(2S)-2-methyl-5-oxo-2H-pyrrole-1-carbonyl]pyrroridine-1-yl]-3-methyl-1-oxobutan-2-yl]-methylamino]-4-oxobutan-2-yl]acetate or a salt thereof.

[0060] In another embodiment, the above compositions include microcholine B or a salt thereof. In some variations, the above compositions include [(2S,3S)-3-[[(2S)-2-[[(2R,4R)-2,4-dimethyloctanoyl]-methylamino]-4-methylpentanoyl]amino]-4-[methyl-[(2S)-3-methyl-1-[(2S)-2-[(2S)-2-methyl-5-oxo-2H-pyrrole-1-carbonyl]pyrroridine-1-yl]-1-oxobutan-2-yl]amino]-4-oxobutan-2-yl]acetate or a salt thereof.

[0061] In a particular embodiment, the above composition is [ka] or including salts thereof (including any isomer of those mentioned above).

[0062] In one embodiment, the above composition is [ka] or a salt thereof.

[0063] In some embodiments, the above composition comprises at least one of the following compounds in Table A below, or salts thereof. [Table A-1] [Table A-2] [Table A-3] [Table A-4] [Table A-5]

[0064] In some embodiments, the above composition comprises at least one of the following compounds in Table A' below, or any salt thereof. [Table A-6] [Table A-7] [Table A-8] [Table A-9] [Table A-10]

[0065] In some variations, the compositions described herein may include the compounds described herein (including compounds of formulas (I), (II), (II-A), (II-B), (III), (III-A), (IV), and (IV-A)), as well as one or more isomers of the compounds in Tables A and A'. Compounds having the same molecular formula but different bonding properties or order of their atoms or their atomic arrangement in space are called "isomers." Isomers having the same bonding order of their atoms but different atomic arrangements in space are called "stereoisomers." A diastereomer is a stereoisomer that has opposite stereoconfigurations at one or more chiral centers and is not an enantiomer. A stereoisomer having one or more chiral centers that are non-overlapping mirror images of each other is called an "enantiomer." If a compound has a chiral center, for example, if a carbon atom is bonded to four different groups, a pair of enantiomers is possible. Enantiomers can be characterized by the absolute stereoconfiguration of their chiral center, described by the R- and S-order rules of Cahn, Ingold, and Prelog, or indicated as dextrorotatory or levorotatory by the manner in which the molecule rotates the plane of polarization. The prefixes d and l or (+) and (-) are used to indicate the rotation of plane polarization by the compound, with (-) or l meaning that the compound is levorotatory. Compound A with the prefix (+) or d is dextrorotatory. Chiral compounds can exist either as individual enantiomers or as mixtures thereof. A mixture containing equal proportions of the above enantiomers is called a "racemic mixture" or "racemate."

[0066] In certain embodiments, the compositions described herein include compounds of formula (I), (II), (II-A), (II-B), (III), (III-A), (IV), or (IV-A), or racemic mixtures of the compounds of Tables A and A'. In certain embodiments, the compounds are enriched with at least about 90% by weight of one diastereomer or enantiomer. In other embodiments, the compounds are enriched with at least about 95% by weight, 98% by weight, or 99% by weight of one diastereomer or enantiomer.

[0067] In some variations, the compositions described herein may contain salts of the compounds described herein (including the compounds of formulas (I), (II), (II-A), (II-B), (III), (III-A), (IV), and (IV-A)), as well as one or more salts of the compounds in Tables A and A'. In certain variations, the salts are pharmaceutically acceptable salts. The term “pharmaceutically acceptable salt” means a salt that retains the biological efficacy and properties of a free base or free acid, and is not biologically or otherwise undesirable.

[0068] General Synthesis of Compounds The compounds provided herein (including compounds of formulas (I), (II), (II-A), (II-B), (III), (III-A), (IV), and (IV-A), as well as the exemplary compounds in Tables A and A') may be synthesized according to the following general scheme 1. The reactions described in the general scheme and the following examples section can be readily adapted for the preparation of the compounds disclosed herein. For example, the preparation of compounds not exemplified in this disclosure may be successfully carried out by modifications obvious to those skilled in the art, for example, by using other suitable reagents known in the art other than those described, or by conventional modifications of reaction conditions, reagents, and starting materials. General Scheme 1 [ka]

[0069] The exemplary compounds in Tables A and A' can be synthesized according to the general scheme 1 described above, where: Z is [ka] Or it is an alkoxy, and here R 2a is H, oxo, or optionally substituted alkyl; R 2x is an alkyl group that is optionally substituted with -OH or -COOH; R 2y is H or alkyl; or R 2x and R 2y These, together with the atoms to which they are bonded, form a five-membered heterocycle, which may be substituted as needed; R 3 is an alkyl, cycloalkyl, or alkenyl; R 4 is H or alkyl; Each R 5 and R 8 These are, independently, hydrophobic side chains of Ala, Val, Ile, Leu, Met, Phe, Tyr, Trp, or Gly, where the above hydrophobic side chains are substituted as needed; R 6 is H or alkyl; R 7 These are -OH, -O(C=O)alkyl, -SH, or -S(C=O)alkyl.

[0070] The reactions described in the General Scheme and the Examples section below can be readily adapted to prepare the compounds disclosed herein. For example, in some variations, reagent R1 may be N-methyl-L-leucine benzyl ester p-toluenesulfonate, and the variable R in formula (IV-A) may be 4 and R 5 It may be substituted with other suitable compounds to generate the corresponding other portion.

[0071] An illustrative procedure for the general scheme (Scheme 1) is provided below.

[0072] Process 1(R 3 COOH condensation. Combine a coupling reagent (e.g., N,N'-carbonyldiimidazole (CDI)) with a suitable solvent (e.g., dichloromethane). Cool this solution. Separately, combine R1 with a suitable solvent (e.g., dichloromethane) and add a suitable base (e.g., diisopropylethylamine (DIPEA)). Once the suspension becomes clear, add the cooled CDI suspension. Once the resulting second suspension becomes clear, continue the reaction under dry conditions (e.g., under a CaCl2 drying tube) until complete. Once complete, the reaction mixture undergoes a workup including extraction with a suitable organic solvent (e.g., ethyl acetate), the organic layer is dried (e.g., with MgSO4), filtered, and the solvent is removed to obtain the crude product (e.g., a viscous oil).

[0073] Further solvents (e.g., dichloromethane) are added to this crude product. 3 COOH, a coupling reagent (e.g., 1-hydroxybenzotriazole hydrate (HOBt hydrate)), and a catalyst (e.g., CuBr2) are added. Once the reaction is complete, the reaction mixture undergoes a workup including quenching (e.g., with an aqueous solution of HCl) and extraction with a suitable organic solvent (e.g., dichloromethane). The organic layer is washed with an aqueous solution (e.g., NaHCO3), dried (e.g., with MgSO4), filtered, and the solvent removed to obtain the crude product (e.g., an oily substance) (P1). [ka]

[0074] Step 2 (Condensation of P1 and R2). P1 is added to an organic solvent (e.g., methanol) and a catalyst (e.g., Pd / C). The reaction is stirred under H2, then filtered to remove the solvent and obtain the crude product (e.g., an oily substance) (P1 acid).

[0075] Combine the coupling reagent (e.g., N,N'-carbonyldiimidazole (CDI)) with a suitable solvent (e.g., dichloromethane). Cool this solution. Separately, combine R2 with a similarly suitable solvent (e.g., dichloromethane), and add a suitable base (e.g., diisopropylethylamine (DIPEA)). Once the suspension becomes clear, add the cooled CDI suspension. Once the resulting second suspension becomes clear, continue the reaction under dry conditions (e.g., under a CaCl2 drying tube) until complete. Once complete, the reaction mixture undergoes a workup including extraction with a suitable organic solvent (e.g., ethyl acetate), the organic layer is dried (e.g., with MgSO4), filtered, and the solvent is removed to obtain the crude product (e.g., a viscous oil).

[0076] Further solvent (e.g., dichloromethane) is added to this crude product. To this, the P1 acid (from above), a coupling reagent (e.g., 1-hydroxybenzotriazole hydrate (HOBt hydrate)), and a catalyst (e.g., CuBr2) are added. Once the reaction is complete, the reaction mixture undergoes a workup including quenching (e.g., with an aqueous solution of HCl) and extraction with a suitable organic solvent (e.g., dichloromethane). The organic layer is washed with an aqueous solution (e.g., NaHCO3), dried (e.g., with MgSO4), filtered, and the solvent is removed to obtain the crude product (e.g., an oily substance) (P2). [ka]

[0077] Step 3 (Condensation of P2 and R3). P2 is added to a suitable organic solvent (e.g., methanol) and a suitable catalyst (e.g., Pd / C). The reaction mixture is stirred under H2, then filtered to remove the solvent and obtain a crude product (e.g., an oily substance) (P2 acid).

[0078] Combine the coupling reagent (e.g., N,N'-carbonyldiimidazole (CDI)) with a suitable solvent (e.g., dichloromethane). Cool this solution. Separately, combine R3 with a suitable solvent (e.g., dichloromethane), and add a suitable base (e.g., diisopropylethylamine (DIPEA)). Once the suspension becomes clear, add the cooled CDI suspension. Once the resulting second suspension becomes clear, continue the reaction under dry conditions (e.g., under a CaCl2 drying tube) until complete. Once complete, the reaction mixture undergoes a workup including extraction with a suitable organic solvent (e.g., ethyl acetate), the organic layer is dried (e.g., with MgSO4), filtered, and the solvent is removed to obtain the crude product (e.g., a viscous oil).

[0079] Further solvents (e.g., dichloromethane) are added to this crude product. To this, P2 acid (from above), a suitable coupling reagent (e.g., 1-hydroxybenzotriazole hydrate (HOBt hydrate)), and a suitable catalyst (e.g., CuBr2) are added. Once the reaction is complete, the reaction mixture undergoes a workup including quenching (e.g., with an aqueous solution of HCl) and extraction with a suitable organic solvent (e.g., dichloromethane). The organic layer is washed with an aqueous solution (e.g., NaHCO3), dried (e.g., with MgSO4), filtered, and the solvent is removed to obtain the crude product (e.g., an oily substance) (P3). [ka]

[0080] Step 4 (Condensation of P3 with cis-hydroxyproline 4-methylpyrrolidinamide). P3 is added to a suitable organic solvent (e.g., methanol) and a suitable catalyst (e.g., Pd / C). The reaction is stirred under H2, then filtered to remove the solvent and obtain the crude product (e.g., an oily substance) (P3 acid).

[0081] A suitable coupling reagent (e.g., N,N'-carbonyldiimidazole (CDI)) is combined with a suitable solvent (e.g., dichloromethane). This solution is cooled. Separately, R4 is combined with a similarly suitable solvent (e.g., dichloromethane), to which a suitable base (e.g., diisopropylethylamine (DIPEA)) is added. Once the suspension becomes clear, the cooled CDI suspension is added to it. Once the resulting second suspension becomes clear, the reaction is continued under dry conditions (e.g., under a CaCl2 drying tube) until complete. Once complete, the reaction mixture undergoes a workup including extraction with a suitable organic solvent (e.g., ethyl acetate), the organic layer is dried (e.g., with MgSO4), filtered, and the solvent is removed to obtain the crude product (e.g., a viscous oil).

[0082] Further solvents (e.g., dichloromethane) are added to this crude product. Then, a P3 acid (from above), a coupling reagent (e.g., 1-hydroxybenzotriazole hydrate (HOBt hydrate)), and a catalyst (e.g., CuBr2) are added. Once the reaction is complete, the reaction mixture undergoes a workup including quenching (e.g., with an aqueous solution of HCl) and extraction with a suitable organic solvent (e.g., dichloromethane). The organic layer is washed with an aqueous solution (e.g., NaHCO3), dried (e.g., with MgSO4), filtered, and the solvent is removed to obtain the crude product (e.g., an oily substance) (formula P). [ka]

[0083] Other components In some embodiments, the composition for respiratory treatment may further comprise one or more additional components. In some variations, the additional components comprise trace amounts of fatty acid triglyceride components. In some variations, the additional components comprise saturated acids. In certain variations, the additional components comprise caproic acid, caprylic acid, capric acid, lauric acid, behenic acid, or lignoceric acid, or any combination thereof.

[0084] In some variations, the above additional components include monounsaturated acids. In certain variations, the above additional components include myristoleic acid, heptadecenoic acid, elaidic acid, gadreic acid, erucic acid, brassic acid, and / or nervonic acid.

[0085] In some variations, the above further components include polyunsaturated acids. In certain variations, the above further components include gamma-linolenic acid, columbinic acid, stearidonic acid, mead acid, and / or dihomo-gamma-linolenic acid.

[0086] In other variations, the above further components include small organic molecules. In some variations, the above further components include terpenes (e.g., ligustilides), sesquiterpenes (e.g., germacrene), phenols (e.g., thymol, eugenol, carvacrol), alcohols (e.g., linalool, citronellol, terpineol), sesquiterpene alcohols (e.g., bisabolol, santalol), ketones (e.g., thujone, pinacamphone, italidone), esters (e.g., linalyl acetate, geranyl acetate, citronellyl formate), lactones and coumarins (e.g., helenaline, elecampane, furocoumarin), ethers (e.g., chavicol), steroid derivatives (e.g., sitosterol, stigmasterol), and / or phthalide derivatives (e.g., 3-butylidene-4,5-dihydrophthalide).

[0087] In some variations, the above further components include other lipopeptides. In some variations, the above further components include linear and / or cyclic lipopeptides. In certain variations, the above further components include itulin A, hoiamide, heronamide, laxaphycin, apraamide, dragonamide, gageotetrin, lyngbyabellin, cyclodycidin, parguerine, pumilacidine, sulforeido lipopeptide, fengisin, mebamamide, penicimutamide, sulfoglycolipid, halovir, kahalalide, and / or tuftosin.

[0088] In some variations of the aforementioned further components described, the compound may exist in salt form (including pharmaceutically acceptable salt forms).

[0089] Condition, disease, or disorder In some cases, the compositions provided herein (including compositions comprising compounds of formulas (I), (II), (II-A), (II-B), (III), (III-A), (IV), and (IV-A)) may be used to treat inflammatory conditions, disorders, or diseases (including respiratory conditions, disorders, or diseases). In some embodiments, the condition, disorder, or disease is inflammation of the respiratory tract. In some cases, a method is provided for treating an inflammatory condition, disorder, or disease in a person in need, the method comprising the step of administering the compositions provided herein to the person.

[0090] In some variations, “treatment” or “doing treatment” refers to an approach to obtain a beneficial or desired outcome, including a clinical result. Beneficial or desired clinical outcomes may include one or more of the following: (i) To reduce one or more symptoms arising from the above-mentioned condition, disease, or disorder; (ii) to reduce the severity of the above-mentioned disease and / or to stabilize the above-mentioned condition, disease, or disability (for example, to slow the exacerbation of the above-mentioned condition, disease, or disability); (iii) To slow the spread of the above-mentioned condition, disease, or disorder; (iv) To slow or delay the recurrence of the above-mentioned condition, disease or disability, and / or the progression of the above-mentioned condition, disease or disability; (v) to improve the disease condition and / or to provide remission (whether partial or complete) of the condition, disease or disorder and / or to reduce the dose of one or more other therapies required to treat the condition, disease or disorder; (vi) to improve the quality of life; and / or (vii) Prolonged survival.

[0091] In some embodiments, the compositions provided herein (including compositions comprising compounds of formulas (I), (II), (II-A), (II-B), (III), (III-A), (IV), and (IV-A)) may be used to treat asthma, pneumonia, bronchiectasis, emphysema, tuberculosis, pneumothorax, pulmonary fibrosis, fibrotic alveolitis, chronic obstructive pulmonary disease (COPD), allergic rhinitis, chronic sinusitis (CRS), and acute respiratory disease syndrome.

[0092] In some embodiments, the condition, disease, or disorder is a chronic inflammatory disorder. In a particular embodiment, the chronic inflammatory disorder is a chronic inflammatory disorder of the airways. In a particular variation, the condition, disease, or disorder is an inflammatory lung disease. In some variations, the condition, disease, or disorder includes narrowing and / or swelling of the airways (which in turn causes dyspnea and induces cough, wheezing, and / or shortness of breath). In a particular variation, the condition, disease, or disorder is asthma. In a particular variation, the asthma is bronchial asthma. In one variation, the condition, disease, or disorder includes steroid-resistant asthma and airway narrowing.

[0093] In other embodiments, the above-mentioned condition, disease, or disorder is an allergy or allergic inflammation.

[0094] In other embodiments, the condition, disease, or disorder is a viral respiratory disease. In some variations, the condition, disease, or disorder is severe acute respiratory syndrome. In certain variations, the severe acute respiratory syndrome is caused by a coronavirus.

[0095] In some variations, the individuals experiencing the above need are those with impaired lung function. In certain variations, these individuals with impaired lung function have fluid buildup in the alveoli. This fluid can leak into the alveoli from the smallest blood vessels in the lungs due to the breakdown of the protective membrane in the alveoli. The membrane that normally holds this fluid within the blood vessels can be destroyed due to a disruption of the immune system resulting from a serious illness or injury. This fluid enters the alveoli, preventing them from being filled with enough air, which means that less oxygen reaches the bloodstream. This deprives organs of the oxygen they need to function, which can lead to multiple organ failure and death.

[0096] In one embodiment, a method is provided for treating a hospitalized person with lung impairment in need, the method comprising the step of administering to the person a composition provided herein (including a composition comprising compounds of formulas (I), (II), (II-A), (II-B), (III), (III-A), (IV), and (IV-A)) to reduce or delay the need to provide the person with assisted respiration.

[0097] In some variations, “delaying” the onset of a condition, disease, or disorder means to defer, hinder, slow, retard, stabilize, and / or postpone the onset of the condition, disease, or disorder. This delay may be of varying lengths depending on the history of the condition, disease, or disorder and / or the individual being treated.

[0098] In other aspects, the compositions provided herein (including compositions comprising compounds of formulas (I), (II), (II-A), (II-B), (III), (III-A), (IV), and (IV-A)) improve anti-inflammatory efficacy by reducing eosinophil effector function. Accordingly, in certain embodiments, a method is provided for reducing eosinophil effector function in a person in need, the method comprising the step of administering the compositions provided herein (including compositions comprising compounds of formulas (I), (II), (II-A), (II-B), (III), (III-A), (IV), and (IV-A)) to the person to reduce eosinophil effector function.

[0099] Patient subgroups In some embodiments, the methods provided herein involve the process of treating a person in need. In certain embodiments, the person is substantially resistant to medical and surgical interventions for treating an inflammatory condition, disorder, or disease described herein. In one embodiment, the person exhibits or has resistance to steroid treatment. For example, in one variation, the person has asthma that is resistant to steroid treatment.

[0100] In some of the variations mentioned above, the person is a child. In certain variations, the person is under 18 years old, under 12 years old, under 10 years old, under 5 years old, under 2 years old, or under 1 year old; or between 2 and 12 years old.

[0101] formulation In some embodiments, the compositions provided herein (including compositions comprising compounds of formulas (I), (II), (II-A), (II-B), (III), (III-A), (IV), and (IV-A)) are formulated for oral administration. Suitable forms for oral administration may include, for example, tablets, pills, capsules, cachets, sugar-coated tablets, lozenges, liquids, gels, syrups, slurries, elixirs, suspensions, aerosols, or powders.

[0102] In certain embodiments, the pharmaceutical compositions described herein are in the form of syrups, capsules, and softgels (e.g., including chewable gummies).

[0103] Techniques relating to the formulation and administration of the above compositions can be found in Remington's Pharmaceutical Sciences, 18th edition, Mack Publishing Co, Easton, Pa., 1990. The pharmaceutical compositions described herein may be manufactured using any conventional method (e.g., mixing, dissolution, granulation, sugar-coating masking, levigating, emulsification, encapsulation, capture, melt-spinning, spray-drying, or lyophilization processes). The optimal pharmaceutical formulation can be determined by those skilled in the art depending on the route of administration and the desired dose. Such formulations may affect the physical state, stability, in vivo release rate, and in vivo clearance rate of the administered drug.

[0104] In some variations, the compositions provided herein are administered to humans as unit doses in the form of syrups, capsules, and softgels (including, for example, chewable gummies), as described herein. In one variation, “unit dosage form” refers to physically discontinuous units that may exist in a pharmaceutically acceptable carrier, which constitute a unit dose (each unit comprising a predetermined amount of the composition provided herein, or a composition containing a biologically active substance isolated from the composition provided herein).

[0105] As used herein, "pharmaceutically acceptable" refers to substances that are not biologically or otherwise undesirable, e.g., the material can be incorporated into a pharmaceutical composition administered to an individual without causing significant undesirable biological effects or interacting in a harmful manner with any of the other components of the composition in which it is included. Pharmaceutically acceptable carriers or excipients preferably thus meet the required standards of toxicological and manufacturing testing and / or are included in the Inactive Ingredient Guide prepared by the U.S. Food and Drug Administration in some embodiments.

[0106] In other variations, the compositions provided herein are formulated for aerosol delivery.

[0107] Dosage In some embodiments, the methods provided include administering to a human in need an effective amount of a composition provided herein (including compositions comprising a compound of formula (I), (II), (II-A), (II-B), (III), (III-A), (IV) and (IV-A)). In some variations, "effective amount" is intended to mean such an amount of a composition or biologically active substance of the invention that should be effective in a given treatment modality. In a particular variation, an effective amount of a composition provided herein reduces eosinophil effector function in a human and thereby treats a human suffering from a condition, disease or disorder described herein or alleviates existing symptoms of such a condition, disease or disorder.

[0108] In some variations, exemplary dosing levels of microcortin for humans can be between 0.01 mg and 100 mg per kg of human body weight.

[0109] The final dosing regimen is determined by the attending physician in view of good medical practice, taking into account various factors that modify the action of the salmon oil composition, or a composition comprising a biologically active substance isolated from the salmon oil composition provided herein, the identity and severity of the disease state, the responsiveness of the subject, the age, condition, weight, sex and diet of the subject, and the severity of any infections. Further factors that may be considered include the timing and frequency of administration, drug combinations, responsiveness, and tolerance / response to treatment. Further refinement of the appropriate dosage for a treatment involving any of the formulations mentioned herein is routinely done by those skilled in the art without undue experimentation, particularly in view of the disclosed dosing information and assays, as well as the pharmacokinetic data observed in human clinical trials.

[0110] An effective amount can be in the form of one or more doses, i.e., a single dose or multiple doses may be required to achieve the desired treatment endpoint. In certain embodiments, the salmon oil composition, or a composition comprising a biologically active substance isolated from the salmon oil composition provided herein, is administered once, twice, or three times a day. In certain embodiments, the composition provided herein is administered once or twice a day. In certain embodiments, the composition provided herein is administered once a day.

[0111] Manufactured Articles and Kits The compositions provided herein (including compositions comprising the compounds of formulas (I), (II), (II-A), (II-B), (III), (III-A), (IV) and (IV-A)) can be formulated, prepared, placed in suitable containers, and labeled for use in the treatment of the indicated conditions, diseases or disorders in a pharmaceutically acceptable carrier, excipient or other ingredient. Thus, in certain aspects, manufactured articles (e.g., containers containing dosage forms of the salmon oil composition, or a composition comprising a biologically active substance isolated from the composition provided herein, and labels containing instructions for the use of such compositions) are also provided.

[0112] In some embodiments, the manufactured article is a dosage form of the composition provided herein, and a container containing one or more pharmaceutically acceptable carriers, excipients, or other components. In one embodiment of the manufactured article described herein, the dosage form is a syrup, a capsule, and a softgel (e.g., a chewable gummy).

[0113] In certain circumstances, a kit is also provided. For example, in some embodiments, the kit may include a package insert containing instructions for the dosage form of the composition provided herein and for the use of the composition / active substance in the treatment of a condition, disease, or disorder. The instructions for use in the kit relate to the treatment of respiratory inflammation or airway inflammation (e.g., asthma). In one variation, the instructions for use in the kit relate to the treatment of bronchial asthma. In another variation, the instructions for use in the kit relate to the treatment of severe acute respiratory syndrome.

[0114] The labels and package inserts for each of the above-described manufactured articles and kits include instructions for the treatment of any of the conditions, diseases, or disorders described herein. In some embodiments, the labels include instructions for the treatment of inflammatory conditions, disorders, or diseases (including respiratory conditions, disorders, or diseases). In some variations, the labels include instructions for the treatment of chronic inflammatory disorders of the airways. In one variation, the labels include instructions for the treatment of asthma (e.g., bronchial asthma and / or asthma resistant to steroid treatment). In other embodiments, the labels include instructions for the treatment of viral respiratory diseases (e.g., severe acute respiratory syndrome (e.g., severe acute respiratory syndrome caused by coronavirus)).

[0115] Unless otherwise explicitly stated, terms such as "one, a (a)" and "one, an (an)" refer to one or more.

[0116] In some variations, “about” refers to the normal range of error for each value, which is readily known to those skilled in the art. References to “about” a value or parameter herein include (and are described) embodiments relating to the value or parameter itself. For example, “about x” includes and is described to “x” itself. In some embodiments, the term “about” used in connection with a measurement or to modify a value, unit constant, or range of values ​​refers to a variation of ±2%.

[0117] In some variations, “between” two values ​​or parameters as used herein includes (and is described as) embodiments that include those two values ​​or parameters themselves. For example, a statement referring to “between x and y” includes a statement of “x” and “y” themselves.

[0118] Enumerated embodiments The following listed embodiments represent several aspects of the present invention. 1. A method for treating an inflammatory condition, disorder, or disease in a person in need, the method comprising the step of administering to the person a composition comprising at least one lipopeptide in an effective dose to treat the inflammatory condition, disorder, or disease. Here, the lipopeptide is [2,4-alkyl-substituted octanoyl]-[N-methylamino acid having a hydrophobic side chain]-[amino acid having a polar, uncharged side chain]-[N-methylamino acid having a hydrophobic side chain]-N-[(4-hydroxy-2-pyrrolidinyl)carbonyl]-5-methyl-3-pyrrolin-2-one, or a salt thereof (including any isomer of the aforementioned); or Here, the lipopeptide is the compound of formula (I): [ka] or their salts (including any isomer of those mentioned above), where: R 1 is a moiety of at least one optionally substituted amino acid; R 2 teeth, [ka] And here: R 2a is H or an optionally substituted alkyl; R 2x is an alkyl group that is optionally substituted with -OH or -COOH; R 2y is H or alkyl; or R 2x and R 2y These, together with the atoms to which they are bonded, form a five-membered heterocycle, which may be substituted as needed; R 3 It is an alkyl group. method. 2. The method according to Embodiment 1, wherein the inflammatory condition, disorder, or disease is a chronic inflammatory disorder of the airway. 3. The method according to Embodiment 1, wherein the inflammatory condition, disorder, or disease is asthma. 4. The method according to Embodiment 1, wherein the inflammatory condition, disorder, or disease is bronchial asthma. 5. A method for treating a respiratory condition, disorder, or disease in a person in need, the method comprising the step of administering to the person a composition comprising at least one lipopeptide in an effective dose to treat an inflammatory condition, disorder, or disease. Here, the lipopeptide is [2,4-alkyl-substituted octanoyl]-[N-methylamino acid having a hydrophobic side chain]-[amino acid having a polar, uncharged side chain]-[N-methylamino acid having a hydrophobic side chain]-N-[(4-hydroxy-2-pyrrolidinyl)carbonyl]-5-methyl-3-pyrrolin-2-one, or a salt thereof (including any isomer of the aforementioned); or The lipopeptide is a compound of formula (I): [ka] or a salt thereof (including any isomers of the foregoing), wherein: R 1 is at least one optionally substituted amino acid moiety; R 2 is

Chemical formula

[0119] Examples The following examples are illustrative and not intended to limit any aspect of this disclosure.

[0120] Synthesis Examples Structural verification was performed by obtaining the predicted M+ ions for all synthesized final analogs. All mass-resolved LC / MS data were obtained.

[0121] Example 1 Synthesis of compound 1b Step 1 (Condensation of racemic 2,4-dimethyloctanoic acid with pTos.N-methyl-L-Leu-OBn). Add 162 mg of N,N'-carbonyldiimidazole (CDI) followed by 1 ml of dichloromethane to a round-bottom, single-neck reaction flask equipped with a micromagnetic stirring bar, and stir gently. Seal the reaction flask with a rubber septum containing a thermoprobe. Cool the reaction flask to 0°C (ice bath).

[0122] In another round-bottom, single-neck reaction flask equipped with a micromagnetic stirring bar, N-methyl-L-leucine benzyl ester p-toluenesulfonate (pTos.MeN-Leu-OBn) (407 mg) is added, followed by dichloromethane. To the resulting white suspension, diisopropylethylamine (DIPEA) (129 mg) is added. The suspension becomes clear and is added to the cooled CDI suspension using a syringe over 10 minutes. The suspension becomes clear and is stirred under a CaCl2 dry tube at room temperature (RT) approximately 25°C, with completion monitored by TLC. The reaction flask is placed in a rotary evaporator, concentrated, extracted twice with ethyl acetate, the ethyl acetate layer is dried with MgSO4, filtered, and the mixture is passed through the rotary evaporator until a viscous oily substance is obtained.

[0123] To this oily substance, 3 ml of dichloromethane is added and stirred at RT for 10 minutes, then 2,4-dimethyloctanoic acid (172 mg), 1-hydroxybenzotriazole hydrate (HOBt hydrate) (2 mg), and CuBr2 (10 mg) are added. The reaction flask is closed with a rubber septum and stirred at RT for 24 hours. Once the reaction is complete (TLC), the mixture is transferred to an Erlenmeyer reaction flask, diluted with dichloromethane, quenched with an aqueous solution of 0.5 N HCl, extracted twice with dichloromethane, washed with NaHCO3, dried over MgSO4, filtered, and concentrated by rotary evaporator to obtain a colorless oily substance (371 mg) (intermediate 1.1). LCMS shows an accurate M+ at 389.570; 95.1 area%. [ka]

[0124] Step 2 (Condensation of Intermediate 1.1 with OAc-L-Thr-OBn). Intermediate 1.1 (389 mg), dry methanol, and 10% Pd / C (40 mg) are added to a round-bottom, single-neck reaction flask equipped with a micromagnetic stirring bar. The reaction mixture is stirred under an H2 atmosphere (balloon) for 2 hours, filtered, and subjected to a rotary evaporator to obtain a pale yellow oily substance (intermediate 1.1 acid).

[0125] In a round-bottom, single-neck reaction flask equipped with a micromagnetic stirring bar, add N,N'-carbonyldiimidazole (CDI) (162 mg), followed by dichloromethane, and stir gently. Seal the reaction flask with a rubber septum containing a thermoprobe. Cool the reaction flask to 0°C (ice bath).

[0126] In a round-bottom, single-neck reaction flask equipped with a micromagnetic stirring bar, 287 mg of OAc-L-threonine benzyl ester hydrochloride (HCl.OAc-Thr-OBn) is added, followed by dichloromethane. To the resulting white suspension, 129 mg of diisopropylethylamine (DIPEA) is added. The suspension becomes clear and is added to the cooled CDI suspension using a syringe over 10 minutes. The suspension becomes clear and is stirred under a CaCl2 drying tube at room temperature for 20 hours. The reaction is monitored by TLC for completion. The reaction flask is placed in a rotary evaporator, concentrated, extracted twice with ethyl acetate, the ethyl acetate layer is dried with MgSO4, filtered, and the mixture is passed through the rotary evaporator until a viscous oily substance is obtained.

[0127] Dichloromethane is added to the oily substance and stirred at RT for 10 minutes. Then, intermediate 1.1 acid (from above), 1-hydroxybenzotriazole hydrate (HOBt hydrate) (2 mg) and CuBr2 (10 mg) are added. The reaction flask is closed with a rubber septum and stirred at RT for 24 hours. Once the reaction is complete (TLC), the mixture is transferred to an Erlenmeyer reaction flask, diluted with dichloromethane, quenched with an aqueous solution of 0.5 N HCl, extracted twice with dichloromethane, washed with NaHCO3, dried over MgSO4, filtered, and concentrated by rotary evaporator to obtain a pale yellow oily substance (452 ​​mg) (intermediate 1.2). LCMS shows an accurate M+ at 532.711; 90.7 area%. [ka]

[0128] Step 3 (Condensation of Intermediate 1.2 with MeN-L-Val-OBn). Intermediate 1.2 (532 mg), dry methanol, and 10% Pd / C (40 mg) are added to a round-bottom, single-neck reaction flask equipped with a micromagnetic stirring bar. The reaction mixture is stirred under an H2 atmosphere (balloon) for 2 hours, filtered, and subjected to a rotary evaporator to obtain a pale yellow oily substance (intermediate 1.2 acid).

[0129] In a round-bottom, single-neck reaction flask equipped with a micromagnetic stirring bar, add N,N'-carbonyldiimidazole (CDI) (162 mg), followed by dichloromethane, and stir gently. Seal the reaction flask with a rubber septum containing a thermoprobe. Cool the reaction flask to 0°C (ice bath).

[0130] In a round-bottom, single-neck reaction flask equipped with a micromagnetic stirring bar, 393 mg of N-methyl-L-valinebenzyl ester 4-toluenesulfonate (pTos.MeN-L-Val-OBn) CAS # 42492-62-6 is added, followed by dichloromethane. To the resulting white suspension, 129 mg of diisopropylethylamine (DIPEA) is added. The suspension becomes clear and is added to a cooled CDI suspension reaction flask using a syringe over 10 minutes. The suspension becomes clear and is stirred under a CaCl2 drying tube at room temperature for 20 hours. The reaction is monitored by TLC for completion. The reaction flask is placed in a rotary evaporator, concentrated, extracted twice with ethyl acetate, the ethyl acetate layer is dried with MgSO4, filtered, and the mixture is passed through the rotary evaporator until a viscous oily mixture is obtained.

[0131] Dichloromethane is added to this oily substance and stirred at RT for 10 minutes. Then, intermediate 1.2 acid (from above), 1-hydroxybenzotriazole hydrate (HOBt hydrate) (2 mg) and CuBr2 (10 mg) are added. The reaction flask is closed with a rubber septum and stirred at RT for 24 hours. Once the reaction is complete (TLC), the mixture is transferred to an Erlenmeyer reaction flask, diluted with dichloromethane (8 mg), quenched with an aqueous solution of 0.5 N HCl, extracted twice with dichloromethane, washed with NaHCO3, dried over MgSO4, filtered, and concentrated by rotary evaporator to obtain a pale yellow oily substance (568 mg) (intermediate 1.3). LCMS shows an accurate M+ at 645.869; 91.0 area%. [ka]

[0132] Step 4 (Condensation of intermediate 1.3 with cis-hydroxyproline 4-methylpyrrolidinamide). Intermediate 1.3 (645 mg), dry methanol, and 10% Pd / C (40 mg) are added to a round-bottom, single-neck reaction flask equipped with a micromagnetic stirring bar. The reaction mixture is stirred under an H2 atmosphere (balloon) for 2 hours, filtered, and subjected to a rotary evaporator to obtain a pale yellow oily substance (intermediate 1.3 acid).

[0133] In a round-bottom, single-neck reaction flask equipped with a micromagnetic stirring bar, add N,N'-carbonyldiimidazole (CDI) (162 mg), followed by 1 ml of dichloromethane, and stir gently. Seal the reaction flask with a rubber septum containing a thermoprobe. Cool the reaction flask to 0°C (ice bath).

[0134] In a 20 ml round-bottom, single-neck reaction flask equipped with a micromagnetic stirring bar, cis-hydroxyproline 4-methylpyrrolidinamide (210 mg) is added, followed by dichloromethane (10 ml). Diisopropylethylamine (DIPEA) (129 mg) is then added to this mixture, and this is added to a cooled CDI suspension reaction flask using a syringe over 10 minutes. The suspension is stirred at room temperature (RT) approximately 25°C for 20 hours under a CaCl2 drying tube. The reaction is monitored by TLC for completion. The reaction flask is placed in a rotary evaporator, concentrated, extracted twice with ethyl acetate, the ethyl acetate layer is dried with MgSO4, filtered, and the mixture is passed through the rotary evaporator until a viscous oily substance is obtained.

[0135] Dichloromethane is added to this oily substance and stirred at RT for 10 minutes. Then, intermediate 1.3 acid (from above), 1-hydroxybenzotriazole hydrate (HOBt hydrate) (2 mg) and CuBr2 (10 mg) are added. The reaction flask is closed with a rubber septum and stirred at RT for 24 hours. Once the reaction is complete (TLC), the mixture is transferred to a 25 ml Erlenmeyer reaction flask, diluted with dichloromethane, quenched with an aqueous solution of 0.5 N HCl, extracted twice with dichloromethane, washed with NaHCO3, dried over MgSO4, filtered, and concentrated by rotary evaporator to obtain a pale yellow oily substance (401 mg) (compound 1b). LCMS shows an accurate M+ at 747.478; 78.4 area%, which is the same as the genuine microcholine A sample. [ka]

[0136] Example 2 Synthesis of compound 5a Step 1 (Condensation of octanoic acid with pTos.N-methyl-L-Leu-OBn). Add N,N'-carbonyldiimidazole (CDI) (162 mg), followed by dichloromethane, to a round-bottom, single-neck reaction flask equipped with a micromagnetic stirring bar, and stir gently. Seal the reaction flask with a rubber septum containing a thermoprobe. Cool the reaction flask to 0°C (ice bath).

[0137] In a round-bottom, single-neck reaction flask equipped with a micromagnetic stirring bar, N-methyl-L-leucine benzyl ester p-toluenesulfonate (PTS.HMeN-Leu-OBn) (407 mg), followed by dichloromethane, is added. To the resulting suspension, diisopropylethylamine (DIPEA) (129 mg) is added. The suspension becomes clear and is added to a cooled CDI suspension reaction flask using a syringe over 10 minutes. The suspension becomes clear and is stirred under a CaCl2 drying tube at room temperature for 20 hours. The reaction is monitored by TLC for completion. The reaction flask is placed in a rotary evaporator, concentrated, extracted twice with ethyl acetate, the ethyl acetate layer is dried with MgSO4, filtered, and the mixture is passed through the rotary evaporator until a viscous oily substance is obtained.

[0138] To this oily substance, 3 ml of dichloromethane is added and stirred at RT for 10 minutes, then octanoic acid (144 mg), 1-hydroxybenzotriazole hydrate (HOBt hydrate) (2 mg), and CuBr2 (10 mg) are added. The reaction flask is closed with a rubber septum and stirred at RT for 24 hours. Once the reaction is complete (TLC), the mixture is transferred to an Erlenmeyer reaction flask, diluted with dichloromethane, quenched with an aqueous solution of 0.5 N HCl, extracted twice with dichloromethane, washed with NaHCO3, dried over MgSO4, filtered, and concentrated by rotary evaporator to obtain a colorless oily substance (380 mg) (intermediate 5.1). LCMS shows an accurate M+ at 361.517; 96.4 area%. [ka]

[0139] Intermediate 5.1 is converted to compound 5b using the same steps 2, 3, and 4 as shown in Example 1 to obtain 413 mg of a yellow oily substance (compound 5b). LCMS shows an accurate M+ at 719.908; 81.7 area%. [ka]

[0140] Example 3 Synthesis of compound 6a Step 1 (Condensation of racemic 2,4-dimethyloctanoic acid with L-Leu-Obn). Add N,N'-carbonyldiimidazole (CDI) (162 mg), followed by dichloromethane, to a round-bottom, single-neck reaction flask equipped with a micromagnetic stirring bar, and stir gently. Seal the reaction flask with a rubber septum containing a thermoprobe. Cool the reaction flask to 0°C (ice bath).

[0141] In a round-bottom, single-neck reaction flask equipped with a micromagnetic stirring bar, N-methyl-L-leucine benzyl ester p-toluenesulfonate (L-Leu-OBn) (221 mg), followed by dichloromethane, is added. To the resulting white suspension, diisopropylethylamine (DIPEA) (129 mg) is added. The suspension becomes clear and is added to a cooled CDI suspension reaction flask using a syringe over 10 minutes. The suspension becomes clear and is stirred under a CaCl2 drying tube at room temperature for 20 hours. The reaction is monitored by TLC for completion. The reaction flask is placed in a rotary evaporator, concentrated, extracted twice with ethyl acetate, the ethyl acetate layer is dried with MgSO4, filtered, and the mixture is passed through the rotary evaporator until a viscous oily substance is obtained.

[0142] Dichloromethane is added to this oily substance and stirred at RT for 10 minutes, then 2,4-dimethyloctanoic acid (172 mg), 1-hydroxybenzotriazole hydrate (HOBt hydrate) (2 mg), and CuBr2 (10 mg) are added. The reaction flask is closed with a rubber septum and stirred at RT for 24 hours. Once the reaction is complete (TLC), the mixture is transferred to an Erlenmeyer reaction flask, diluted with dichloromethane, quenched with an aqueous solution of 0.5 N HCl, extracted twice with dichloromethane, washed with NaHCO3, dried over MgSO4, filtered, and concentrated by rotary evaporator to obtain a colorless oily substance (333 mg) (intermediate 6.1). LCMS shows an accurate M+ at 375.544; 96.6 area%. [ka]

[0143] Step 2. Intermediate 6.1 is condensed with OAc-L-threonine benzyl ester hydrochloride in exactly the same manner as shown in Step 2 of Example 1 to obtain intermediate 6.2 (407 mg). LCMS shows an accurate M+ at 518.684; 95.2 area%. [ka]

[0144] Steps 3-4. Intermediate 6.2 is first condensed with L-valinebenzyl ester 4-toluenesulfonate in the same manner as shown in Step 3 of Example 1. The resulting product is then condensed with cis-hydroxyproline 4-methylpyrrolidinone amide in the same manner as shown in Step 4 of Example 1 to obtain compound 6a (412 mg) as a pale yellow oil. LCMS shows an accurate M+ at 719.907; 88.1 area%. [ka]

[0145] Example 4 Synthesis of Compound 7a 2,4-dimethyloctanoic acid is condensed with N-methyl-L-glycine benzyl ester HCl in the same manner as shown in step 1 of Example 1. [ka] This is obtained and further condensed with OAc-L-threonine benzyl ester hydrochloride as shown in step 2 of Example 1, [ka] This is obtained and further condensed with N-methyl-L-glycine benzyl ester HCl as shown in step 3 of Example 1, [ka] This is obtained and finally condensed with cis-hydroxyproline 4-methylpyrrolidinoneamide as shown in step 4 of Example 1 to obtain compound 7a (357 mg). LCMS shows an accurate M+ at 649.775; 86.4 area%. [ka]

[0146] Example 5 Synthesis of compound 8a Intermediate 1.1 is condensed with L-threonine benzyl ester hydrochloride by a process similar to that shown in step 2 of Example 1. [ka] This is obtained and further condensed with N-methyl-L-valinebenzyl ester 4-toluenesulfonate in the same manner as described in step 3 of Example 1. The resulting product is then condensed with cis-hydroxyproline 4-methylpyrrolidinone amide in the same manner as described in step 4 of Example 1 to obtain compound 8a (521 mg) as a yellow oil. LCMS shows an accurate M+ at 705.924; 79.5 area%. [ka]

[0147] Example 6 Synthesis of compound 9a Intermediate 1.1 is condensed with OAc-L-serine benzyl ester hydrochloride using the process shown in step 2 of Example 1. [ka] This is obtained and further condensed with N-methyl-L-valinebenzyl ester 4-toluenesulfonate in the same manner as described in step 3 of Example 1. The resulting product is then condensed with cis-hydroxyproline 4-methylpyrrolidinone amide in the same manner as shown in step 4 of Example 1 to obtain compound 9a (668 mg) as a colorless oil. LCMS shows an accurate M+ at 733.934; 82.4 area%. [ka]

[0148] Example 7 Synthesis of compound 10a Steps 1-3. Steps 1, 2, and 3 were carried out as in the synthesis of compound 1b to obtain intermediate 1.3. This was further condensed with 3-hydroxy-2-(methylamino)-1-(5-methyl-2-oxo-3-cyclopenten-1-yl)-1-propanone as shown in step 4 below.

[0149] Step 4. Add intermediate 1.3 (645 mg), dry methanol, and 10% Pd / C (40 mg) to a round-bottom, single-neck reaction flask equipped with a micromagnetic stirring bar. Stir the reaction mixture under an H2 atmosphere (balloon) for 2 hours, filter, and pass through a rotary evaporator to obtain a pale yellow oily substance (intermediate 1.3 acid).

[0150] In a round-bottom, single-neck reaction flask equipped with a micromagnetic stirring bar, add N,N'-carbonyldiimidazole (CDI) (162 mg), followed by 1 ml of dichloromethane, and stir gently. Seal the reaction flask with a rubber septum containing a thermoprobe. Cool the reaction flask to 0°C (ice bath).

[0151] In a 20 ml round-bottom, single-neck reaction flask equipped with a micromagnetic stirring bar, 197 mg of 3-hydroxy-2-(methylamino)-1-(5-methyl-2-oxo-3-cyclopenten-1-yl)-1-propanone is added, followed by 10 ml of dichloromethane. 129 mg of diisopropylethylamine (DIPEA) is then added to the cooled CDI suspension using a syringe over 10 minutes. The suspension is stirred at room temperature for 20 hours under a CaCl2 drying tube. The reaction is monitored by TLC for completion. The reaction flask is placed in a rotary evaporator, concentrated, extracted twice with ethyl acetate, the ethyl acetate layer is dried over MgSO4, filtered, and the mixture is passed through the rotary evaporator until a yellow oily substance is obtained.

[0152] Dichloromethane is added to the above oily substance and stirred in RT for 10 minutes. Then, intermediate 1.3 acid (from above), 1-hydroxybenzotriazole hydrate (HOBt hydrate) (2 mg) and CuBr2 (10 mg) are added. The reaction flask is closed with a rubber septum and stirred in RT for 24 hours. Once the reaction is complete (TLC), the mixture is transferred to a 25 ml Erlenmeyer reaction flask, diluted with dichloromethane (8 ml), quenched with aqueous solution of 0.5 N HCl (10 ml), extracted twice with 10 ml dichloromethane, washed with NaHCO3, dried over MgSO4, filtered, and concentrated using a rotary evaporator to obtain compound 10a (514 mg), a light brown oily substance. LCMS shows accurate M+ at 721.923; 75.8 area%. [ka]

[0153] Example 8 Synthesis of compound 11a Intermediate 1.1 is condensed with L-cysteine ​​benzyl ester hydrochloride using a process similar to that shown in step 2 of Example 1. [ka] This is obtained and further condensed with N-methyl-L-valinebenzyl ester 4-toluenesulfonate in the same manner as described in step 3 of Example 1. The resulting product is then condensed with L-proline 4-methylpyrrolidinamide (194 mg) in the same manner as shown in step 4 of Example 1 to obtain compound 11a (439 mg) as a yellow oil. LCMS shows an accurate M+ at 691.967; 72.1 area%. [ka]

[0154] Example 9 Synthesis of compound 12a Intermediate 1.3 is condensed with L-proline-maleimide (194 mg) in the same manner as shown in step 4 of Example 1 to obtain compound 12a (539 mg) as a brown oily substance. LCMS shows an accurate M+ at 731.918; 77.8 area%. [ka]

[0155] Example 10 Synthesis of compound 13a Step 1 (Condensation of cyclohexanecarboxylic acid with N-methyl-L-Leu-OBn). Add 162 mg of N,N'-carbonyldiimidazole (CDI), followed by 1 ml of dichloromethane, to a round-bottom, single-neck reaction flask equipped with a micromagnetic stirring bar, and stir gently. Seal the reaction flask with a rubber septum containing a thermoprobe. Cool the reaction flask to 0°C (ice bath).

[0156] In a round-bottom, single-neck CDI reaction flask equipped with a micromagnetic stirring bar, add N-methyl-L-leucine benzyl ester p-toluenesulfonate (PTS.HMeN-Leu-OBn) (407 mg), followed by dichloromethane (2 ml). To the resulting suspension, add diisopropylethylamine (DIPEA) (129 mg). Once the suspension becomes clear, add it to a cooled CDI suspension reaction flask using a syringe over 10 minutes. Once the suspension becomes clear, continue stirring under a CaCl2 drying tube at room temperature for 20 hours. Monitor the reaction for completion by TLC. Place the reaction flask in a rotary evaporator, concentrate, extract twice with ethyl acetate, dry the ethyl acetate layer with MgSO4, filter, and return to the rotary evaporator until a viscous oily mixture is obtained.

[0157] To this oily substance, 3 ml of dichloromethane is added and stirred at RT for 10 minutes, then cyclohexanecarboxylic acid (128 mg), 1-hydroxybenzotriazole hydrate (HOBt hydrate) (2 mg), and CuBr2 (10 mg) are added. The reaction flask is closed with a rubber septum and stirred at RT for 24 hours. Once the reaction is complete (TLC), the mixture is transferred to a 25 ml Erlenmeyer reaction flask, diluted with dichloromethane (7 ml), quenched with 0.5 N HCl aqueous solution (10 ml), extracted twice with 10 ml of dichloromethane, washed with NaHCO3, dried over MgSO4, filtered, and concentrated by rotary evaporator to obtain a yellow oily substance. LCMS shows an accurate M+ at 345.475; 94.2 area%. [ka] This was condensed with L-Thr-OBn in a process similar to step 2 of Example 1, then condensed with N-methyl-L-valine.OBn as in step 3 of Example 1, and finally condensed with cis-hydroxyproline 4-methylpyrrolidinonamide as in step 4 of Example 1 to obtain 413 mg of a light brown oily compound 13a - LCMS showed an accurate M+ at 663.801; 82.7 area%. [ka]

[0158] Example 11 Synthesis of compound 14a EPA acid (CAS number 10417-94-4) (302 mg) was condensed with N-methyl-L-Leu-OBn in the same manner as shown in compound 13a to obtain a brown oily substance (LCMS showed accurate M+ at 519.756; 92.5 area %). [ka] This was condensed with L-Thr-OBn in a process similar to step 2 of Example 1, then condensed with N-methyl-L-valine.OBn as in step 3 of Example 1, and finally condensed with cis-hydroxyproline 4-methylpyrrolidinonamide as in step 4 of Example 1 to obtain 684 mg of a brown viscous oil compound 14a. LCMS showed an accurate M+ at 838.083; 77.0 area%. [ka]

[0159] Example 12 Synthesis of compound 15a DHA acid (CAS number 6217-54-5) (328 mg) was condensed with N-methyl-L-Leu-OBn in the same manner as shown in Example 1 to obtain a brown, waxy solid (LCMS showed accurate M+ at 545.793; 90.6 area %). [ka] This was condensed with L-Thr-OBn in a process similar to step 2 of Example 1, then condensed with N-methyl-L-valine.OBn as in step 3 of Example 1, and finally condensed with cis-hydroxyproline 4-methylpyrrolidinoneamide as in step 4 of Example 1 to obtain 660 mg of a brown solid compound 15a - LCMS showed an accurate M+ at 864.120; 75.3 area%. [ka]

[0160] Example 13 Synthesis of compound 16a Steps 1-3. Steps 1, 2, and 3 are carried out exactly as in the synthesis of compound 5a to obtain intermediate 16.3, a yellow oily substance (562 mg) as shown below. [ka] This was obtained and condensed with 1-{[(2S,4S)-4-hydroxy-2-pyrrolidinyl]carbonyl}-2-piperidinone (212 mg) in the same manner as shown in step 4 of Example 1 to obtain compound 16a, a yellow waxy solid (504 mg) (LCMS shows accurate M+ at 707.897; 91.8 area %). [ka]

[0161] Example 14 Synthesis of compound 17a Intermediate 16.3 was condensed with OMe-L-hydroxyproline (145 mg) in the same manner as shown in step 4 of Example 1 to obtain compound 17a, a brown viscous oil (504 mg) (LCMS showed an accurate M+ at 640.808; 84.3 area %). [ka]

[0162] Example 15 Synthesis of compound 18a Step 1 (Condensation of octanoic acid with N-methyl-L-Phe-OBn). Add 162 mg of N,N'-carbonyldiimidazole (CDI) followed by 1 ml of dichloromethane to a round-bottom, single-neck reaction flask equipped with a micromagnetic stirring bar, and stir gently. Seal the reaction flask with a rubber septum containing a thermoprobe. Cool the reaction flask to 0°C (ice bath).

[0163] In a round-bottom, single-neck reaction flask of CDI equipped with a micromagnetic stirring bar, add N-methyl-L-phenylalanine benzyl ester (MeN-Phe-OBn) (269 mg), followed by dichloromethane (2 ml). To the resulting suspension, add diisopropylethylamine (DIPEA) (129 mg). Add this solution to the cooled CDI suspension reaction flask using a syringe over 10 minutes. Continue stirring under a CaCl2 dry tube at room temperature for 20 hours. Monitor the reaction for completion by TLC. Place the reaction flask in a rotary evaporator, concentrate, extract twice with ethyl acetate, dry the ethyl acetate layer with MgSO4, filter, and return to the rotary evaporator until a viscous oily mixture is obtained.

[0164] To this oily substance, 3 ml of dichloromethane is added and stirred at RT for 10 minutes, then octanoic acid (144 mg), 1-hydroxybenzotriazole hydrate (HOBt hydrate) (2 mg), and CuBr2 (10 mg) are added. The reaction flask is closed with a rubber septum and stirred at RT for 24 hours. Once the reaction is complete (TLC), the mixture is transferred to a 25 ml Erlenmeyer reaction flask, diluted with dichloromethane (7 ml), quenched with 0.5 N HCl aqueous solution (10 ml), extracted twice with 10 ml of dichloromethane, washed with NaHCO3, dried over MgSO4, filtered, and concentrated by rotary evaporator to obtain a colorless oily substance (406 mg) (intermediate 18.1). LCMS shows an accurate M+ at 395.533; 93.9 area%. [ka]

[0165] The above compounds are sequentially condensed with OAc-L-Thr.OBn, and then condensed with N-methyl-L-valinebenzyl ester 4-toluenesulfonate. [ka] This is then condensed with L-hydroxyproline-maleimide (210 mg) in the same manner as shown in step 4 of Example 1 to obtain compound 18a (551 mg) as a yellow oil. LCMS shows an accurate M+ at 753.880; 78.4 area%. [ka]

[0166] Example 16 Synthesis of compound 19a Repeat steps 1 and 2 from Example 2, [ka] This is obtained and condensed with N-methyl-L-methionine benzyl ester in a manner similar to that shown in step 3 of Example 1, and then condensed with L-hydroxyproline-maleimide (210 mg) in the same manner as shown in step 4 to obtain compound 19a (594 mg) as a brown oily substance. LCMS shows an accurate M+ at 751.932; 78.4 area%. [ka]

[0167] Example 17 Synthesis of compound 20a Step 1 (Condensation of octanoic acid with pTos.N-methyl-L-Ile-OBn). Add 162 mg of N,N'-carbonyldiimidazole (CDI), followed by 1 ml of dichloromethane, to a round-bottom, single-neck reaction flask equipped with a micromagnetic stirring bar, and stir gently. Seal the reaction flask with a rubber septum containing a thermoprobe. Cool the reaction flask to 0°C (ice bath).

[0168] In a round-bottom, single-neck reaction flask of CDI equipped with a micromagnetic stirring bar, add N-methyl-L-isoleucine benzyl ester p-toluenesulfonate CAS # 201544-39-0 (pTos.MeN-Ile-OBn) (407 mg), followed by dichloromethane (2 ml). To the resulting suspension, add diisopropylethylamine (DIPEA) (129 mg). Once the suspension becomes clear, add it to a cooled CDI suspension reaction flask using a syringe over 10 minutes. Once the suspension becomes clear, continue stirring under a CaCl2 drying tube at room temperature for 20 hours. Monitor the reaction for completion by TLC. Place the reaction flask in a rotary evaporator, concentrate, extract twice with ethyl acetate, dry the ethyl acetate layer with MgSO4, filter, and return to the rotary evaporator until a viscous oily mixture is obtained.

[0169] To this oily substance, 3 ml of dichloromethane is added and stirred at RT for 20 minutes. Then, octanoic acid (144 mg), 1-hydroxybenzotriazole hydrate (HOBt hydrate) (2 mg), and CuBr2 (10 mg) are added. The reaction flask is closed with a rubber septum and stirred at RT for 36 hours. Once the reaction is complete (TLC), the mixture is transferred to a 25 ml Erlenmeyer reaction flask, diluted with dichloromethane (7 ml), quenched with 0.5 N HCl aqueous solution (10 ml), extracted twice with 10 ml of dichloromethane, washed with NaHCO3, dried over MgSO4, filtered, and concentrated using a rotary evaporator to obtain a pale yellow oil. [ka] This is obtained and condensed with OAc-L-Thr-OBn as shown in step 2 of Example 1 to obtain a yellow oily substance. [ka] To obtain this, condense it with N-methyl-L-tryptophan benzyl ester: Add 532 mg of step-2-MA-017, dry methanol and 10% Pd / C (40 mg) to a round-bottom, single-neck reaction flask equipped with a micromagnetic stirring bar. Stir the reaction mixture under an H2 atmosphere (balloon) for 2 hours, filter it, and pass it through a rotary evaporator to obtain a pale yellow oily substance (intermediate 20.2 acid).

[0170] In a round-bottom, single-neck reaction flask equipped with a micromagnetic stirring bar, add 162 mg of N,N'-carbonyldiimidazole (CDI), followed by 1 ml of dichloromethane, and stir gently. Seal the reaction flask with a rubber septum containing a thermoprobe. Cool the reaction flask to 0°C (ice bath).

[0171] In a 10 ml round-bottom, single-neck reaction flask equipped with a micromagnetic stirring bar, add 344 mg of N-methyl-L-tryptophan benzyl ester HCl (N-Me-L-Trp-OBn HCl), followed by 2 ml of dichloromethane. To the resulting suspension, add 129 mg of diisopropylethylamine (DIPEA). Once the suspension becomes clear, add it to a cooled CDI suspension reaction flask using a syringe over 10 minutes. Once the suspension becomes clear / colorless, continue stirring under a CaCl2 dry tube at room temperature for 20 hours. Monitor the reaction by TLC for completion. Place the reaction flask in a rotary evaporator, concentrate, extract twice with ethyl acetate, dry the ethyl acetate layer with MgSO4, filter, and evaporate in the rotary evaporator until a viscous oily mixture is obtained.

[0172] Dichloromethane is added to the oily substance and stirred at RT for 10 minutes. Then, intermediate 20.2 (from above), 1-hydroxybenzotriazole hydrate (HOBt hydrate) (2 mg), and CuBr2 (10 mg) are added. The reaction flask is closed with a rubber septum and stirred at RT for 24 hours. Once the reaction is complete (TLC), the mixture is transferred to a 25 ml Erlenmeyer reaction flask, diluted with dichloromethane (8 ml), quenched with aqueous solution of 0.5 N HCl (10 ml), extracted twice with 10 ml of dichloromethane, washed with NaHCO3, dried over MgSO4, filtered, and concentrated by rotary evaporator to obtain a pale yellow oily substance (485 mg) (intermediate 20.3). LCMS shows an accurate M+ at 704.894; 77.2 area%. [ka] This was condensed with L-hydroxyproline-maleimide (210 mg) in the same manner as shown in step 4 of Example 1 to obtain compound 20a (594 mg) as a pale yellow oil. LCMS showed an accurate M+ at 806.943; 78.4 area%. [ka]

[0173] Biological examples Example 18 Percentage of eosinophil apoptosis in purified human peripheral blood eosinophils in allergies In triplicate, human eosinophils with allergies were placed in RPMI 1640 medium supplemented with IL-5 (50 pM), 1% FBS, and PenStrep, in the presence of 3 μg / mL ApoA-IV (positive control), 10 μg / mL test compound, and formulation vehicle (negative control). Aliquots were removed after 18 hours of incubation, washed twice in PBS, and resuspended in binding buffer. The eosinophils were stained using Annexin V-FITC Apoptosis Detection Kit I (Sigma Aldrich) and immediately analyzed by flow cytometry. Each sample was acquired for 1 minute, and the total number of eosinophils, as well as the percentage of viable cells (annexin V negative) and apoptotic cells (annexin V positive), were recorded on a forward scatter / side scatter plot (standard deviation in this assay is ±2.3%). See Table 1 below for results. [Table 1]

[0174] Example 19 CD11b changes on PMNL surfaces stimulated by 2.5nm CCL11 (100% as baseline) (PMNL) cells were pretreated for 30 minutes with 3 μg / mL ApoA-IV (positive control), 1 μg / mL test compound, and formulation vehicle (negative control), and incubated with serial dilutions of CCL11 at 37°C for 30 minutes. Samples were stained with anti-CD16-PE-Cy5 and anti-CD11b-PE (ICRF44) antibodies. Eosinophils were identified as CD16-negative cells. CD11b upregulation was analyzed by flow cytometry and reported above (standard deviation in this assay is ±2%). See Table 2 below for results. [Table 2]

Claims

1. Lipopeptides, including any isomers, of the following: alkenyl-[N-methyl amino acid having a hydrophobic side chain]-[amino acid having a polar uncharged side chain]-[N-methyl amino acid having a hydrophobic side chain]-N-[(4-hydroxy-2-pyrrolidinyl)carbonyl]-5-methyl-3-pyrrolin-2-one, or alkenyl-[N-methyl amino acid having a hydrophobic side chain]-[amino acid having a polar uncharged side chain]-[N-methyl amino acid having a hydrophobic side chain]-N-[4-hydroxypyrrolidine-2-carbonyl]-1H-[pyrrole-2,5-dione], or alkenyl-[N-methyl amino acid having a hydrophobic side chain]-[amino acid having a polar uncharged side chain]-[N-methyl amino acid having a hydrophobic side chain]-N-[pyrrolidine-2-carbonyl]-1H-[pyrrole-2,5-dione]; A lipopeptide or a salt thereof comprising:

2. Lipopeptide of formula (IV), including any isomers: [C94] or a salt thereof, wherein: R 1 is at least one optionally substituted amino acid moiety; R 2 teeth, [C95] where R 2a is H, oxo or optionally substituted alkyl; R 2x is alkyl optionally substituted with -OH or -COOH; R 2y is H or alkyl; or R 2x and R 2y together with the atom to which they are attached form an optionally substituted 5-membered heterocycle; R 3is alkenyl, Lipopeptides or salts thereof.

3. R 1 is a sequence of three optionally substituted amino acid moieties, or a salt thereof, including any isomer thereof.

4. R 1 is -R 1a -R 1b -R 1c -where: R 1a is an optionally substituted amino acid moiety having a hydrophobic side chain; R 1b is an optionally substituted amino acid moiety having a polar, uncharged side chain; R 1c is an optionally substituted amino acid moiety having a hydrophobic side chain, The lipopeptide of claim 2, or a salt thereof, including any isomer.

5. R 1 is -R 1a -R 1b -R 1c - where: R 1a is an optionally substituted Leu or Phe; R 1b is an optionally substituted Thr; R 1c is optionally substituted Val; The lipopeptide of claim 2, or a salt thereof, including any isomer.

6. R 1 teeth, Leu-Thr-Val, where each Leu and Val is N-methylated; Leu-OAcThr-Val, where each Leu and Val is N-methylated, Leu-OAcThr-Val; Phe-OAcThr-Val, where each Phe and Val is N-methylated; or Phe-Thr-Val, where each Phe and Val is N-methylated; The lipopeptide of claim 2,

7. R 2 teeth, [C96] The lipopeptide according to any one of claims 1 to 6, or a salt thereof, including any isomer thereof,

8. R 2x and R 2y or a salt thereof, including any isomers in which, together with the atom to which they are attached, form an optionally substituted 5-membered heterocycle.

9. R 2 teeth, [C97] The lipopeptide according to any one of claims 1 to 8, or a salt thereof, including any isomer thereof,

10. R 2b The lipopeptide of claim 9, or a salt thereof, including any isomers in which is H or OH.

11. R 2a The lipopeptide according to any one of claims 2 to 10, or a salt thereof, including any isomers in which R is alkyl or oxo.

12. R 3 is C 2 -C 30 The lipopeptide according to any one of claims 2 to 11, including any isomer, or a salt thereof, which is alkenyl.

13. Lipopeptide of formula (IV-A), including any isomers: [C98] or a salt thereof, wherein Z is, [C99] or alkoxy, where R 2a is H, oxo or optionally substituted alkyl; R 2x is alkyl optionally substituted with -OH or -COOH; R 2y is H or alkyl; or R 2x and R 2y together with the atom to which they are attached form an optionally substituted 5-membered heterocycle; R 3 is alkenyl; R 4 is H or alkyl; Each R 5 and R 8 is independently the hydrophobic side chain of Ala, Val, Ile, Leu, Met, Phe, Tyr, Trp, or Gly, where the hydrophobic side chain is optionally substituted; R 6 is H or alkyl; R 7 is -OH, -O(C=O)alkyl, -SH, or -S(C=O)alkyl; Lipopeptides, or salts thereof.

14. Z is, [C100] 14. The lipopeptide of claim 13, or a salt thereof, including any isomer thereof,

15. R 2a is alkyl or oxo, including any isomer thereof.

16. R 2x and R 2y The lipopeptide according to any one of claims 13 to 15, or a salt thereof, including any isomer in which, together with the atom to which they are attached, form a 5-membered heterocycle substituted with -OH.

17. R 3 is C 2- C 30 The lipopeptide according to any one of claims 13 to 16, including any isomer, wherein the lipopeptide is alkenyl, or a salt thereof.

18. R 5 is a hydrophobic side chain of Leu or Phe, including any isomer thereof, the lipopeptide according to any one of claims 13 to 17, or a salt thereof.

19. R 7 is -OH, -O(C=O)CH 3 , -SH, or -S(C=O)CH 3 The lipopeptide according to any one of claims 13 to 18, or a salt thereof, including any isomer thereof,

20. A lipopeptide, including any isomer thereof, comprising: [Case 101-1] [chemical 101-2] or a salt thereof.

21. The lipopeptide may be any of the following, including any isomers: [Case 102-1] [chemical 102-2] 21. The lipopeptide or salt thereof of claim 20,

22. A lipopeptide, including any isomer thereof, comprising: [Case 103-1] [chemical 103-2] [chemical 103-3] or a salt thereof.

23. The lipopeptide may be any of the following, including any isomers: [C104-1] [C104-2] [Case 104-3] 23. The lipopeptide or salt thereof of claim 22,

24. A pharmaceutical composition comprising at least one lipopeptide according to any one of claims 1 to 23 and at least one pharma- ceutically acceptable excipient.

25. A composition for treating an eosinophilic inflammatory condition, disorder or disease in a human in need of such treatment, comprising at least one lipopeptide described in any one of claims 1 to 23.

26. 26. The composition of claim 25, wherein the eosinophilic inflammatory condition, disorder or disease is a chronic inflammatory disorder of the airways.

27. 26. The composition of claim 25, wherein the eosinophilic inflammatory condition, disorder or disease is asthma.

28. 26. The composition of claim 25, wherein the eosinophilic inflammatory condition, disorder or disease is bronchial asthma.

29. A composition for treating an eosinophilic respiratory condition, disorder or disease in a human in need of such treatment, comprising at least one lipopeptide described in any one of claims 1 to 23.

30. 30. The composition of claim 29, wherein the eosinophilic respiratory condition, disorder or disease is a viral respiratory disease.

31. 30. The composition of claim 29, wherein the eosinophilic respiratory condition, disorder or disease is severe acute respiratory syndrome.

32. 30. The composition of claim 29, wherein the severe acute respiratory syndrome is caused by a coronavirus.

33. The composition of any one of claims 25 to 32, wherein the human is substantially resistant to medical and surgical intervention to treat the condition, disorder or disease.

34. The composition of any one of claims 25 to 32, wherein the human is resistant to or has a resistance to steroid treatment.

35. The composition of any one of claims 25 to 32, wherein the human has asthma that is resistant to steroid treatment.

36. The composition of any one of claims 25 to 35, wherein administration of the composition to the human reduces or delays the need to provide assisted breathing to the human.

37. A salmonid oil composition or composition for reducing eosinophil effector function in a human in need thereof, comprising at least one lipopeptide described in any one of claims 1 to 23.

38. 38. The composition of any one of claims 25 to 37, further comprising caproic acid, caprylic acid, capric acid, lauric acid, behenic acid, lignoceric acid, myristoleic acid, heptadecenoic acid, elaidic acid, gadoleic acid, erucic acid, brassidic acid, nervonic acid, gamma linoleic acid, columbic acid, stearidonic acid, mead acid, or dihomo-gamma linoleic acid, or any combination thereof.

39. 39. The composition of any one of claims 25 to 38, further comprising ligustilide, germacrene, thymol, eugenol, carvacrol, linalool, citronellol, terpineol, bisabolol, santalol, thujone, pinacampone, italidone, linalyl acetate, geranyl acetate, citronellyl formate, helenalin, oleander, furocoumarin, chavicol, sitosterol, stigmasterol, or 3-butylidene-4,5-dihydrophthalide, or any combination thereof.

40. 40. The composition of any one of claims 25 to 39, further comprising iturin A, hoiamide, helonamide, laxaficin, apramide, dragonamide, gageotetrin, lyngbyaverin, cyclodiscidin, parguerin, pumilacidin, sulfolaidolipopeptide, fengycin, mebamamide, penisimutamide, sulfoglycolipid, halovir, kahalalide, or tuftsin, or any salt thereof, or any combination of the foregoing.

41. The composition of any one of claims 25 to 40, wherein the composition is administered as a syrup, chewable, capsule or softgel, or wherein the composition is formulated for aerosol administration.

42. A container containing a composition comprising at least one lipopeptide according to any one of claims 1 to 23; and a label containing instructions for use of such composition; (c) an article of manufacture,

43. 43. The article of manufacture of claim 42, wherein the composition is provided in a dosage form.

44. 44. The article of manufacture of claim 42 or 43, wherein the dosage form is a syrup, chewable tablet, capsule or softgel.

45. 44. The article of manufacture of claim 42 or 43, wherein the container is an aerosol container.

46. A dosage form of a composition comprising at least one lipopeptide according to any one of claims 1 to 23; and a package insert containing instructions for use of such composition; Kit including:

47. 47. The kit of claim 46, wherein the dosage form is a syrup, chewable, capsule or softgel, or the dosage form is in an aerosol form.